Global Psychoactive Substances Industry Outlook 2021: Overview, Opportunities, Key Companies and Forecast to 2027
Report Code: KNJ1027919
Publisher: Date of Publish:
No. of Pages: 129 Category: Pharmaceuticals and Healthcare Publisher: Date of Publish:
Executive Summary According to GRD Survey data, the global Psychoactive Substances market was valued at million US$ in 2020 and is expected to reach million US$ by the end of 2027, growing at a CAGR of % in the forecast period between 2021 and 2027. This report studies the Psychoactive Substances market dynamics from angles such as new entries, mergers and acquisitions, fundings, exit and major technology breakthroughs. Market performance is evaluated through market size (value and volume) by players, regions, product types and end industries. This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis. Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Psychoactive Substances in these regions, from 2016 to 2027, covering North America (United States, Canada and Mexico) Europe (Germany, France, UK, Italy, Spain and Russia, etc.) Asia-Pacific (China, Japan, Korea, Southeast Asia, India, Australia) South America (Brazil, Argentina, Colombia, etc.) Middle East and Africa (Turkey, Saudi Arabia, South Africa, etc.) Market Snapshot, By Product Type Stimulants Cannabinoids Hallucinogens Depressants Market Snapshot, By Application Cancer Neuropathic Disorders Spasticity Main Market Players Analyzed in this report, including: Zynerba Pharmaceuticals Tilray Teewinot Life Sciences MedReleaf Australia GW Pharmaceuticals PLC. GD Pharma Enecta. Cyrelian Pty Ltd. Cape Bouvard Technologies Pty Ltd Cannabics Pharmaceuticals Inc. AusCann Group Holdings Pty Ltd. Alpha-CAT The study objectives of this report are: To study and analyze the global Psychoactive Substances market size (value & volume) by company, key regions/countries, products and application, history data from 2016 to 2020, and forecast to 2027. To understand industry structure of Psychoactive Substances market by identifying its various subsegments. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). To identify the key global Psychoactive Substances manufacturers and regional typical players, to define, describe and analyze their sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze the Psychoactive Substances market with respect to individual growth trends, future prospects, and their contribution to the total market. To project the value and volume of Psychoactive Substances submarkets, with respect to key regions (along with their respective key countries). To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market. To strategically profile the key players and comprehensively analyze their growth strategies. In this study, the years considered to estimate the market size of Psychoactive Substances are as follows: History Year: 2016-2020 Base Year: 2020 Estimated Year: 2021 Forecast Year 2021 to 2027 This report includes the estimation of market size in terms of value (million USD) and volume from top-down approach by analyzing major submarkets and their major driving factors, and verified from bottom-up approaches. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified from primary sources. For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered. Key Stakeholders Considered in the study: Raw material vendors Distributors/traders/wholesalers/suppliers Regulatory authorities, including government agencies and NGO Commercial research & development (R&D) institutions Importers and exporters Government organizations, research organizations, and consulting firms Trade/Industrial associations End-use industries
Table of Contents 1 Market Definition & Scope 1.1 Definition & Scope 1.2 Psychoactive Substances Product Specifications 1.3 Main Events (Entry, M&A, Exit, Technology and Capital Activity) 1.4 Global Psychoactive Substances Market Performance and Outlook 2 Market Development Performance under COVID-19 2.1 Influencing Factors of Industry Development in the Next Five Years 2.1.1 Drivers 2.1.2 Restraints 2.1.3 Opportunities 2.2 Porter’s Five Forces Analysis 2.3 Comparison of Alternatives and Psychoactive Substances 3 Supply Chain and Manufacturing Cost Analysis 3.1 Supply Chain Analysis 3.2 Raw Materials and Key Suppliers Analysis 3.2.1 Raw Materials Introduction 3.2.1 Raw Materials Key Suppliers List 3.3 Psychoactive Substances Sales Channel and Distributors Analysis 3.3.1 Psychoactive Substances Sales Channel 3.3.2 Psychoactive Substances Distributors 3.4 Key Buying Industries/Consumers 3.4.1 Major Buyers in Cancer 3.4.2 Major Buyers in Neuropathic Disorders 3.5 Psychoactive Substances Manufacturing Cost Structure Analysis 4 Market Segment: by Type 4.1 Psychoactive Substances Type Introduction 4.1.1 Stimulants 4.1.2 Cannabinoids 4.1.3 Hallucinogens 4.1.4 Depressants 4.2 Global Psychoactive Substances Sales by Type 2016-2021 4.3 Global Psychoactive Substances Revenue by Type 2016-2021 4.4 Global Psychoactive Substances Price by Type 2016-2021 5 Market Segment: by Application 5.1 Psychoactive Substances Type Introduction 5.1.1 Cancer 5.1.2 Neuropathic Disorders 5.1.3 Spasticity 5.2 Global Psychoactive Substances Sales by Application 2016-2021 5.3 Global Psychoactive Substances Revenue by Application 2016-2021 5.4 Global Psychoactive Substances Price by Application 2016-2021 6 Marke Segment: by Region 6.1 Global Psychoactive Substances Market by Region 6.1.1 Global Psychoactive Substances Sales by Regions 6.1.2 Global Psychoactive Substances Revenue by Regions 6.2 North America Psychoactive Substances Market 2016-2021 6.3 Europe Psychoactive Substances Market 2016-2021 6.4 Asia Pacific Psychoactive Substances Market 2016-2021 6.5 South America Psychoactive Substances Market 2016-2021 6.6 Middle East and Africa Psychoactive Substances Market 2016-2021 7 North America 7.1 North America Psychoactive Substances Market by Country 2016-2021 7.1.1 North America Psychoactive Substances Sales by Country 7.1.2 North America Psychoactive Substances Revenue by Country 7.2 United States 7.3 Canada 7.4 Mexico 8 Europe 8.1 Europe Psychoactive Substances Market by Country 2016-2021 8.1.1 Europe Psychoactive Substances Sales by Country 8.1.2 Europe Psychoactive Substances Revenue by Country 8.2 Germany 8.3 France 8.4 UK 8.5 Italy 8.6 Russia 8.7 Spain 9 Asia Pacific 9.1 Asia Pacific Psychoactive Substances Market by Country 2016-2021 9.1.1 Asia Pacific Psychoactive Substances Sales by Country 9.1.2 Asia Pacific Psychoactive Substances Revenue by Country 9.2 China 9.3 Japan 9.4 Korea 9.5 Southeast Asia 9.6 India 9.7 Australia 10 South America 10.1 South America Psychoactive Substances Market by Country 2016-2021 10.1.1 South America Psychoactive Substances Sales by Country 10.1.2 South America Psychoactive Substances Revenue by Country 10.2 Brazil 10.3 Argentina 10.4 Colombia 11 Middle East and Africa 11.1 Middle East and Africa Psychoactive Substances Market by Country 2016-2021 11.1.1 Middle East and Africa Psychoactive Substances Sales by Country 11.1.2 Middle East and Africa Psychoactive Substances Revenue by Country 11.2 Turkey 11.3 Saudi Arabia 11.4 South Africa 12 Key Participants Company Information 12.1 Zynerba Pharmaceuticals 12.1.1 Zynerba Pharmaceuticals Company Information 12.1.2 Zynerba Pharmaceuticals Psychoactive Substances Product Portfolio, Specification and Application 12.1.3 Zynerba Pharmaceuticals Psychoactive Substances Sales, Price, Revenue and Gross Margin (2019-2021) 12.1.4 Zynerba Pharmaceuticals Key Development 12.2 Tilray 12.2.1 Tilray Company Information 12.2.2 Tilray Psychoactive Substances Product Portfolio, Specification and Application 12.2.3 Tilray Psychoactive Substances Sales, Price, Revenue and Gross Margin (2019-2021) 12.2.4 Tilray Key Development 12.3 Teewinot Life Sciences 12.3.1 Teewinot Life Sciences Company Information 12.3.2 Teewinot Life Sciences Psychoactive Substances Product Portfolio, Specification and Application 12.3.3 Teewinot Life Sciences Psychoactive Substances Sales, Price, Revenue and Gross Margin (2019-2021) 12.3.4 Teewinot Life Sciences Key Development 12.4 MedReleaf Australia 12.4.1 MedReleaf Australia Company Information 12.4.2 MedReleaf Australia Psychoactive Substances Product Portfolio, Specification and Application 12.4.3 MedReleaf Australia Psychoactive Substances Sales, Price, Revenue and Gross Margin (2019-2021) 12.4.4 MedReleaf Australia Key Development 12.5 GW Pharmaceuticals PLC. 12.5.1 GW Pharmaceuticals PLC. Company Information 12.5.2 GW Pharmaceuticals PLC. Psychoactive Substances Product Portfolio, Specification and Application 12.5.3 GW Pharmaceuticals PLC. Psychoactive Substances Sales, Price, Revenue and Gross Margin (2019-2021) 12.5.4 GW Pharmaceuticals PLC. Key Development 12.6 GD Pharma 12.6.1 GD Pharma Company Information 12.6.2 GD Pharma Psychoactive Substances Product Portfolio, Specification and Application 12.6.3 GD Pharma Psychoactive Substances Sales, Price, Revenue and Gross Margin (2019-2021) 12.6.4 GD Pharma Key Development 12.7 Enecta. 12.7.1 Enecta. Company Information 12.7.2 Enecta. Psychoactive Substances Product Portfolio, Specification and Application 12.7.3 Enecta. Psychoactive Substances Sales, Price, Revenue and Gross Margin (2019-2021) 12.7.4 GD Pharma Key Development 12.9 Cape Bouvard Technologies Pty Ltd 12.9.1 Cape Bouvard Technologies Pty Ltd Company Information 12.9.2 Cape Bouvard Technologies Pty Ltd Psychoactive Substances Product Portfolio, Specification and Application 12.9.3 Cape Bouvard Technologies Pty Ltd Psychoactive Substances Sales, Price, Revenue and Gross Margin (2019-2021) 12.9.4 Cape Bouvard Technologies Pty Ltd Key Development 12.8 Cyrelian Pty Ltd. 12.8.1 Cyrelian Pty Ltd. Company Information 12.8.2 Cyrelian Pty Ltd. Psychoactive Substances Product Portfolio, Specification and Application 12.8.3 Cyrelian Pty Ltd. Psychoactive Substances Sales, Price, Revenue and Gross Margin (2019-2021) 12.8.4 Cyrelian Pty Ltd. Key Development 12.11 AusCann Group Holdings Pty Ltd. 12.11.1 AusCann Group Holdings Pty Ltd. Company Information 12.11.2 AusCann Group Holdings Pty Ltd. Psychoactive Substances Product Portfolio, Specification and Application 12.11.3 AusCann Group Holdings Pty Ltd. Psychoactive Substances Sales, Price, Revenue and Gross Margin (2019-2021) 12.11.4 AusCann Group Holdings Pty Ltd. Key Development 12.12 Alpha-CAT 12.12.1 Alpha-CAT Company Information 12.12.2 Alpha-CAT Psychoactive Substances Product Portfolio, Specification and Application 12.12.3 Alpha-CAT Psychoactive Substances Sales, Price, Revenue and Gross Margin (2019-2021) 12.12.4 Alpha-CAT Key Development 13 Global Psychoactive Substances Market Forecast by Region by Type and by Application 13.1 Global Psychoactive Substances Sales, Revenue Forecast 2022-2027 13.2 Global Psychoactive Substances Forecast by Regions 13.2.1 Global Psychoactive Substances Sales Forecast by Region 2022-2027 13.2.2 Global Psychoactive Substances Revenue Forecast by Region 2022-2027 13.3 Global Psychoactive Substances Forecast by Type 13.3.1 Global Psychoactive Substances Sales Forecast by Type 2022-2027 13.3.2 Global Psychoactive Substances Revenue Forecast by Type 2022-2027 13.3.3 Global Psychoactive Substances Price Forecast by Type 2022-2027 13.4 Global Psychoactive Substances Forecast by Application 13.4.1 Global Psychoactive Substances Sales Forecast by Application 2022-2027 13.4.2 Global Psychoactive Substances Revenue Forecast by Application 2022-2027 13.4.3 Global Psychoactive Substances Price Forecast by Application 2022-2027 14 Analyst Views and Conclusions 15 Methodology and Data Source 15.1 Methodology 15.2 Research Data Source 15.2.1 Secondary Data 15.2.2 Primary Data 15.2.3 Market Size Estimation 15.3 Legal Disclaimer
NEED Help?
If you need any help or guidance, please feel free to call us.
USA : +1 (661) 636 6162
INDIA : +91 9325802062
or
Write us on : sales@kandjmarketresearch.com